Skip to main content

Advertisement

SpringerLink
Log in

Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. O’Shea JJ, Holland SM, Staudt LM (2013) JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368(2):161–170

    Article  PubMed  Google Scholar 

  2. von Hofsten J, Johnsson Forsberg M, Zetterberg M (2016) Cytomegalovirus retinitis in a patient who received ruxolitinib. N Engl J Med 374(3):296–297

    Article  Google Scholar 

  3. Chen Y-H, Lee C-H, Pei S-N (2015) Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis. Leuk Lymphoma 56(5):1528–1529

    Article  PubMed  Google Scholar 

  4. Palandri F, Polverelli N, Catani L, Vianelli N (2014) Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge. Ann Hematol 94(3):519–520

    Article  PubMed  Google Scholar 

  5. Hopman RK, Lawrence SJ, Oh ST (2014) Disseminated tuberculosis associated with ruxolitinib. Leukemia 28(8):1750–1751

    Article  CAS  PubMed  Google Scholar 

  6. Colomba C, Rubino R, Siracusa L, Lalicata F, Trizzino M, Titone L, Tolomeo M (2012) Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes 5:552

    Article  PubMed  PubMed Central  Google Scholar 

  7. Shi JG, Chen X, McGee RF, Landman RR, Emm T, Lo Y, Scherle PA, Punwani NG, Williams WV, Yeleswaram S (2011) The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol 51(12):1644–1654

    Article  CAS  PubMed  Google Scholar 

  8. Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y (2012) The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol 52(6):809–818

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Cancer University Institute of Toulouse Oncopole, Toulouse, France

    Benoit Branco & Christian Recher

  2. Laboratory of Pharmacokinetics and Toxicology, Toulouse University Hospital, Toulouse, France

    David Metsu

  3. EA4553, Université Paul Sabatier, Toulouse, France

    David Metsu

  4. Department of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, France

    Marine Dutertre, Bruno Marchou, Pierre Delobel & Guillaume Martin-Blondel

  5. Université Toulouse III, Toulouse, France

    Marine Dutertre, Bruno Marchou, Pierre Delobel, Christian Recher & Guillaume Martin-Blondel

  6. INSERM U1043 - CNRS UMR 5282, Centre de Physiopathologie Toulouse-Purpan, Toulouse, France

    Guillaume Martin-Blondel

  7. Department of Infectious and Tropical Diseases, Centre Hospitalier Universitaire de Toulouse, Place du Docteur Baylac TSA 40031, 31059, Toulouse cedex 9, France

    Guillaume Martin-Blondel

Authors
  1. Benoit Branco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Metsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marine Dutertre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bruno Marchou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pierre Delobel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christian Recher
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Guillaume Martin-Blondel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guillaume Martin-Blondel.

Ethics declarations

Conflict of interest

Dr. Recher reports grants from Novartis, during the conduct of the study, and grants from Celgene, grants from Sunesis, grants from Amgen, and grants from Chugai, outside the submitted work.

The other authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Branco, B., Metsu, D., Dutertre, M. et al. Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib. Ann Hematol 95, 1207–1209 (2016). https://doi.org/10.1007/s00277-016-2684-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-016-2684-0

Keywords

Search

Navigation